Blood Thinner Study for Stroke Prevention in Brief Atrial Fibrillation Linked to Stress
Tests a blood thinner in adults over 55 with atrial fibrillation triggered by stress.
Plain-language title generated from the registry record
Registry title: Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
Key facts
- Where
- Berlin, Coburg, Göttingen, Leipzig, Muenster, and Munich, GermanySee the 6 sites
- Phase
- Phase 4
Where in Germany
- Deutsches Herzzentrum der CharitéBerlin, GermanyTaking people
- SANA Kliniken Oberfranken Coburg GmbHCoburg, GermanyTaking people
- University Medical Center GöttingenGöttingen, GermanyTaking people
- Universitatsklinikum LeipzigLeipzig, GermanyTaking people
- University Hospital MuensterMuenster, GermanyTaking people
- LMU University Hospital MunichMunich, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Population Health Research Institute
- Trial code
- NCT03968393EU 2023-509142-35-00
- Record updated
- 12 January 2026
- Original description
Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring transiently with stress and additional stroke risk factors.Read full original descriptionShow less
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress - The ASPIRE-AF Trial
Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial fibrillation occurring transiently with stress and additional stroke risk factors.
Inclusion: have ≥1 episode of clinically important AFOTS during any of the following conditions:; noncardiac surgery in the past 35 days, with at least an overnight hospital admission aftersurgery; noncardiac day surgery resulting in a large enough physiological insult to be able to cause AFOTS, as judged by the local investigator; or; acute medical illness requiring hospital admission in the past 35 days and resulting in a large enough physiological insult to be able to cause AFOTS, as judged by the local investigator; sinus rhythm at the time of randomization; any of the following high-risk criteria:; age 55-64 years, and having either known cardiovascular disease, recent major vascular surgery, a CHA2DS2VASc score ≥3, or an elevated postoperative troponin level; age 65-74 years, and having either known cardiovascular disease, recent major vascular surgery, a CHA2DS2VASc score ≥2, or an elevated postoperative troponin level; OR; age ≥75 years; provide written informed consent.
Exclusion: history of documented chronic AF prior to noncardiac surgery; expected to be non-compliant with follow-up and/or study medications; known life expectancy less than 1 year due to concomitant disease; previously enrolled in the trial; any cardiac diagnosis as the primary reason for hospital admission; severe renal insufficiency (CrCl <20 ml/min); acute stroke in the past 14 days; underwent cardiac surgery in the past 35 days; history of nontraumatic intracranial, intraocular, or spinal bleeding; hemorrhagic disorder or bleeding diathesis; need for long-term systemic anticoagulation; ongoing need for long-term dual antiplatelet treatment; contraindication to oral anticoagulation; severe liver cirrhosis (i.e., Child-Pugh Class C); women who are pregnant, breastfeeding, or of childbearing potential who are not taking effective contraception; OR.